Success of haploidentical hematopoietic stem cells transplantation in the treatment of graft failure

Pagliuca, Simona; Legendre, Hugo; Morin, Sarah; Rabian, Florence; Naveau, Louise; Zine, Maryem; Wang, Lining; Marchand, Tony; Coman, Téreza; Xhaard, Aliénor; Ferry, C; Robin, Marie; Latour, Régis Peffault de; Socié, Gèrard; Fontbrune, Flore Sicre de

doi:10.1007/s00277-015-2525-6

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, most patients have a haploidentical donor that can be promptly identified and harvested. Our group retransplanted a patient who experienced 2 consecutive graft failures and successfully managed her through a third HSCT with PTCy from her haploidentical son [7]. Therefore, we asked what are the outcomes of haploidentical transplantation using PTCy as GVHD prophylaxis for rescuing graft failure patients.…”

Section: Introductionmentioning

confidence: 99%

Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy

Prata

Resche‐Rigon

Blaise

et al. 2019

Biology of Blood and Marrow Transplantation

Self Cite

View full text Add to dashboard Cite

Prognosis of patients with graft failure is dismal, and retransplantation is the sole option for long-term survival. To address the interest of haploidentical transplantation as a salvage option in this context, we analyzed data from 24 patients with graft failure or loss retransplanted with a haploidentical donor who received post-transplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis (GVHD). Fludarabine-based reduced-intensity conditioning was used in 23 patients and the Baltimore regimen in 14 patients. The median delay between previous and salvage transplantation for graft failure was 63 days (range, 39 to 98). In addition to PTCy, all patients received cyclosporine, and 22 patients also received mycophenolate mofetil for GVHD prophylaxis. With a median followup of 353 days (range, 16 to 2010), 1-year overall survival (OS) was 56% (95% confidence interval, 38% to 81%). Transplant complications accounted for 80% of deaths. The cumulative incidence of neutrophil engraftment at day +30 was 79%. Cumulative incidence of grades II to IV acute GVHD at day 100 was 14%, and 1-year cumulative incidence of chronic GVHD was 31%. One-year cumulative incidence of relapse was 13%. Stem cell source did not impact on engraftment, GVHD, relapse, or OS. Salvage haploidentical transplant with PTCy for rescuing graft failure patients leads to an acceptable 1-year OS and might be a valid option in this poor situation.

show abstract

Section: Introductionmentioning

confidence: 99%

Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy

Prata

Resche‐Rigon

Blaise

et al. 2019

Biology of Blood and Marrow Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

Haploidentical hematopoietic stem cell transplantation in a myelofibrosis patient with primary graft failure

et al. 2018

View full text Add to dashboard Cite

The prognosis of patients affected by myelofibrosis (MF) is usually dismal and allogeneic hematopoietic stem cell transplantation (HSCT) remains the only cure. The number of HSCTs in MF patients has recently increased. However, a major obstacle is still represented by primary graft failure (PGF). Currently there are no definitive guidelines for the treatment of PGF and a second HSCT can be performed only when an allogeneic donor is rapidly available. Herein we report on a MF patient with PGF after an unrelated HSCT, who was rescued by a non-myeloablative, unmanipulated, haploidentical HSCT that resulted in persistent engraftment and bone-marrow fibrosis regression, but not in a long-term disease control. Based on this experience we briefly review the role of different conditioning regimens and hematopoietic stem cell sources in the setting of HSCT for MF patients with PGF. The role of haploidentical donors in MF patients lacking HLAmatched relatives is also discussed.

show abstract

Success of haploidentical hematopoietic stem cells transplantation in the treatment of graft failure

Cited by 2 publications

References 8 publications

Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy

Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Graft Failure Patients: a Report on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy

Haploidentical hematopoietic stem cell transplantation in a myelofibrosis patient with primary graft failure

Contact Info

Product

Resources

About